SLC1A2 and Parkinson disease: Interestingly, among patients with PD and other neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer’s disease (AD), EAAT2 is downregulated, leading to the exacerbation of excitotoxicity due to the low clearance of glutamate from the synapse [41–43].